Mariam Taha1,2, Hesham Abdelbary2, F Patrick Ross3, Alberto V Carli4,5. 1. Ottawa Hospital Research Institute, Ottawa, ON, Canada. 2. Division of Orthopedic Surgery Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. 3. Hospital for Special Surgery, 535 E 70th St, New York, NY, 10021, USA. 4. Division of Orthopedic Surgery Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. CarliA@hss.edu. 5. Hospital for Special Surgery, 535 E 70th St, New York, NY, 10021, USA. CarliA@hss.edu.
Abstract
PURPOSE OF REVIEW: Periprosthetic joint infection (PJI) is a devastating complication after total joint replacement. A main source for antibiotic tolerance and treatment failure is bacterial production of biofilm-a resilient barrier against antibiotics, immune system, and mechanical debridement. The purpose of this review is to explore some novel approaches to treat PJI and biofilm-related infections. RECENT FINDINGS: Innovative treatment strategies of bacterial and biofilm infections revolve around (a) augmenting current therapies, such as improving the delivery and efficiency of conventional antibiotics and enhancing the efficacy of antiseptics and (b) administrating completely new therapeutic modalities, such as using immunotherapy, nanoparticles, lytic bacteriophages, photodynamic therapy, novel antibiotics, and antimicrobial peptides. Several promising treatment strategies for PJI are available to be tested further. The next requirement for most of the novel treatments is reproducing their effects in clinically representative animal models of PJI against clinical isolates of relevant bacteria.
PURPOSE OF REVIEW: Periprosthetic joint infection (PJI) is a devastating complication after total joint replacement. A main source for antibiotic tolerance and treatment failure is bacterial production of biofilm-a resilient barrier against antibiotics, immune system, and mechanical debridement. The purpose of this review is to explore some novel approaches to treat PJI and biofilm-related infections. RECENT FINDINGS: Innovative treatment strategies of bacterial and biofilm infections revolve around (a) augmenting current therapies, such as improving the delivery and efficiency of conventional antibiotics and enhancing the efficacy of antiseptics and (b) administrating completely new therapeutic modalities, such as using immunotherapy, nanoparticles, lytic bacteriophages, photodynamic therapy, novel antibiotics, and antimicrobial peptides. Several promising treatment strategies for PJI are available to be tested further. The next requirement for most of the novel treatments is reproducing their effects in clinically representative animal models of PJI against clinical isolates of relevant bacteria.
Authors: Adam I Edelstein; Kamil T Okroj; Thea Rogers; Craig J Della Valle; Scott M Sporer Journal: J Arthroplasty Date: 2018-02-12 Impact factor: 4.757
Authors: Bhaveen H Kapadia; Richard A Berg; Jacqueline A Daley; Jan Fritz; Anil Bhave; Michael A Mont Journal: Lancet Date: 2015-06-28 Impact factor: 79.321
Authors: Felix Greimel; Christine Scheuerer; Andre Gessner; Michaela Simon; Thomas Kalteis; Joachim Grifka; Achim Benditz; Hans-Robert Springorum; Jens Schaumburger Journal: Drug Des Devel Ther Date: 2017-06-14 Impact factor: 4.162
Authors: Argyris C Hadjimichael; Athanasios F Foukas; Angelos Kaspiris; Dimitris Vasileiou; Spyros Kamariotis; Antonios Stylianakis; Elias S Vasiliadis; Olga D Savvidou; Athanasios Antonopoulos Journal: Infect Prev Pract Date: 2022-07-12
Authors: Anabelle Visperas; Daniel Santana; Alison K Klika; Carlos A Higuera-Rueda; Nicolas S Piuzzi Journal: J Orthop Res Date: 2022-05-06 Impact factor: 3.102